Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆
- DOI
- 10.1016/j.esmoop.2026.108362
- Published
- 2026-09
- Container
- ESMO Open
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2026.108362,
title = {Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5\%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆},
author = {D. Tougeron and J. Xu and E. Raymond and R.A. Hubner and K. Kato and L. Wyrwicz and E. Van Cutsem and S.R. Park and P. Jimenez-Fonseca and T. Kojima and R. Ishihara and A. Avallone and R. Pazo-Cid and K. Wang and S. Yan and J. Shi and X. Kong and H.H. Yoon and F. Lordick},
year = {2026},
journal = {ESMO Open},
doi = {10.1016/j.esmoop.2026.108362},
url = {https://doi.org/10.1016/j.esmoop.2026.108362}
}RIS
TY - JOUR TI - Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆ AU - D. Tougeron AU - J. Xu AU - E. Raymond AU - R.A. Hubner AU - K. Kato AU - L. Wyrwicz AU - E. Van Cutsem AU - S.R. Park AU - P. Jimenez-Fonseca AU - T. Kojima AU - R. Ishihara AU - A. Avallone AU - R. Pazo-Cid AU - K. Wang AU - S. Yan AU - J. Shi AU - X. Kong AU - H.H. Yoon AU - F. Lordick PY - 2026 JO - ESMO Open DO - 10.1016/j.esmoop.2026.108362 UR - https://doi.org/10.1016/j.esmoop.2026.108362 ER -
APA
Tougeron, D., Xu, J., Raymond, E., Hubner, R., Kato, K., Wyrwicz, L., Cutsem, E. V., Park, S., Jimenez-Fonseca, P., Kojima, T., Ishihara, R., Avallone, A., Pazo-Cid, R., Wang, K., Yan, S., Shi, J., Kong, X., Yoon, H., & Lordick, F. (2026). Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆. ESMO Open. https://doi.org/10.1016/j.esmoop.2026.108362
Source records
- crossref · retrieved 2026-09-25T07:06:19.681Z